|
|
| Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
| Bank Loan Ratings | 14.50 | ACUITE B+ | Reaffirmed | Issuer not co-operating* | - |
| Bank Loan Ratings | 5.00 | - | ACUITE A4 | Reaffirmed | Issuer not co-operating* |
| Total Outstanding | 19.50 | - | - |
|
Rating Rationale |
|
Acuité has reaffirmed the long-term rating of ‘ACUITE B+’ (read as ACUITE B plus) and short-term rating of 'ACUITE A4' (read as Acuite A4) on the Rs. 19.50 crore bank facilities of Ujin Pharmachem The rating continues to be flagged as “Issuer Not-Cooperating” and is based on the best available information. |
| About the Company |
|
Ujin Pharmachem, established in 2005 is a Mumbai-based partnership firm promoted by Mr. Umang Mehta and Mr. Jinesh Sheth. The firm is engaged in trading of chemicals, bulk drugs and pharmaceutical products. The firm procures products from manufacturers in and around Mumbai and sells the finished product to traders and manufacturers all over India. The firm also imports around 45 percent of its total purchases from Turkey, USA, Holland and other European countries. |
| Non-cooperation by the issuer/borrower: |
|
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. Acuité believes that information risk is a critical component in such ratings, and non-cooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies. |
| Limitation regarding information availability: |
|
The rating is based on information available from sources other than the issuer/borrower (in the absence of information provided by the issuer/borrower). Acuité endeavored to gather information about the entity/industry from the public domain. Therefore, Acuité cautions lenders and investors regarding the use of such information, on which the indicative credit rating is based. |
| Rating Sensitivity |
|
"No information provided by the issuer / available for Acuite to comment upon." |
| All Covenants |
|
"No information provided by the issuer / available for Acuite to comment upon." |
| Liquidity Position |
|
Not Applicable |
| Outlook |
|
Not Applicable |
| Other Factors affecting Rating |
|
Not Applicable |
| Particulars | Unit | FY 18 (Actual) | FY 17 (Actual) |
| Operating Income | Rs. Cr. | 199.47 | 137.48 |
| PAT | Rs. Cr. | 1.75 | 1.20 |
| PAT Margin | (%) | 0.88 | 0.87 |
| Total Debt/Tangible Net Worth | Times | 1.95 | 2.14 |
| PBDIT/Interest | Times | 1.55 | 1.43 |
| Status of non-cooperation with previous CRA |
|
Not Applicable |
| Any other information |
|
None. |
| Applicable Criteria |
|
• Trading Entities: https://www.acuite.in/view-rating-criteria-61.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
| Note on Complexity Levels of the Rated Instrument |
|
In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’ s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in |
|
| |
|
|
|||||||||||||||||||||||||||
|
|
Contacts |
|
|
|
About Acuité Ratings & Research |
